Maria Gonzalez-Cao, Miguel-Ángel Berciano-Guerrero, Eva Muñoz-Couselo, José Luis Manzano, Pablo Cerezuela-Fuentes, Guillermo Crespo, Ainara Soria, Pablo Ayala de Miguel, Lourdes Gutiérrez Sanz, Carlos Aguado de la Rosa, Almudena García Castaño, Teresa Puértolas, Enrique Espinosa, Javier Medina, Lorena Bellido, Alfonso Berrocal, Margarita Majem, Rafael López Castro, Luis Antonio Fernandez, Francisco Garcia, Maria Rodriguez de la Borbolla, Salvador Martín Algarra, Iván Márquez-Rodas
{"title":"基于抗PD-1抗体的免疫治疗在肢端黑色素瘤患者中的疗效不佳：来自西班牙黑色素瘤组（GEM）注册的结果。","authors":"Maria Gonzalez-Cao, Miguel-Ángel Berciano-Guerrero, Eva Muñoz-Couselo, José Luis Manzano, Pablo Cerezuela-Fuentes, Guillermo Crespo, Ainara Soria, Pablo Ayala de Miguel, Lourdes Gutiérrez Sanz, Carlos Aguado de la Rosa, Almudena García Castaño, Teresa Puértolas, Enrique Espinosa, Javier Medina, Lorena Bellido, Alfonso Berrocal, Margarita Majem, Rafael López Castro, Luis Antonio Fernandez, Francisco Garcia, Maria Rodriguez de la Borbolla, Salvador Martín Algarra, Iván Márquez-Rodas","doi":"10.1007/s12094-025-04018-5","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Acral melanoma (AM) is uncommon in non-Asian race. Limited data exist in non-Asian population.</p><p><strong>Objective: </strong>To analyze the activity of immunotherapy in patients diagnosed with AM in Spain.</p><p><strong>Methods: </strong>We analyzed clinical outcomes of AM in the nationwide Spanish Melanoma Group Registry.</p><p><strong>Results: </strong>69 AM (17 stage III; 52 stage IV) and 724 cutaneous melanoma (CM) (190 stage III; 534 stage IV), predominantly non-Hispanic white. Regarding stage IV, AM patients were older (median 73.6 vs. 66.6 years, p = 0.001) and less often BRAF mutant (9.6% vs. 60.7%, p = 0.0001). First line immunotherapy (49 AM; 316 CM), response rate was 15.0% vs 39.1% (p = 0.0033), median progression free survival was 5.5 (95% CI 3.97-8.23) vs 15.3 months (95% CI 8.97- 26.3) (p = 0.001) and median OS was 17.3 (95% CI 13.32-39.97) versus 43.0 months (95% CI 30.81, NR) (p = 0.007), for AM and CM, respectively. Stage III AM were deeper (T4b in 52.9% vs. 25.3%, p = 0.02). In adjuvant anti PD-1-treated patients (14 AM; 156 CM) median RFS was 10.23 months (95% CI 6.0-NR) in AM versus NR (54.5-NR) in CM (p = 0.017) and 5 year OS was 36.1% vs. 75.8% (p = 0.034).</p><p><strong>Conclusions: </strong>Our data confirms a poor outcome of AM in the Spanish population.</p>","PeriodicalId":50685,"journal":{"name":"Clinical & Translational Oncology","volume":" ","pages":""},"PeriodicalIF":2.5000,"publicationDate":"2025-08-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Poor efficacy of anti PD-1 antibody based immunotherapy in patients with acral melanoma: results from the Spanish Melanoma Group (GEM) registry.\",\"authors\":\"Maria Gonzalez-Cao, Miguel-Ángel Berciano-Guerrero, Eva Muñoz-Couselo, José Luis Manzano, Pablo Cerezuela-Fuentes, Guillermo Crespo, Ainara Soria, Pablo Ayala de Miguel, Lourdes Gutiérrez Sanz, Carlos Aguado de la Rosa, Almudena García Castaño, Teresa Puértolas, Enrique Espinosa, Javier Medina, Lorena Bellido, Alfonso Berrocal, Margarita Majem, Rafael López Castro, Luis Antonio Fernandez, Francisco Garcia, Maria Rodriguez de la Borbolla, Salvador Martín Algarra, Iván Márquez-Rodas\",\"doi\":\"10.1007/s12094-025-04018-5\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background: </strong>Acral melanoma (AM) is uncommon in non-Asian race. Limited data exist in non-Asian population.</p><p><strong>Objective: </strong>To analyze the activity of immunotherapy in patients diagnosed with AM in Spain.</p><p><strong>Methods: </strong>We analyzed clinical outcomes of AM in the nationwide Spanish Melanoma Group Registry.</p><p><strong>Results: </strong>69 AM (17 stage III; 52 stage IV) and 724 cutaneous melanoma (CM) (190 stage III; 534 stage IV), predominantly non-Hispanic white. Regarding stage IV, AM patients were older (median 73.6 vs. 66.6 years, p = 0.001) and less often BRAF mutant (9.6% vs. 60.7%, p = 0.0001). First line immunotherapy (49 AM; 316 CM), response rate was 15.0% vs 39.1% (p = 0.0033), median progression free survival was 5.5 (95% CI 3.97-8.23) vs 15.3 months (95% CI 8.97- 26.3) (p = 0.001) and median OS was 17.3 (95% CI 13.32-39.97) versus 43.0 months (95% CI 30.81, NR) (p = 0.007), for AM and CM, respectively. Stage III AM were deeper (T4b in 52.9% vs. 25.3%, p = 0.02). In adjuvant anti PD-1-treated patients (14 AM; 156 CM) median RFS was 10.23 months (95% CI 6.0-NR) in AM versus NR (54.5-NR) in CM (p = 0.017) and 5 year OS was 36.1% vs. 75.8% (p = 0.034).</p><p><strong>Conclusions: </strong>Our data confirms a poor outcome of AM in the Spanish population.</p>\",\"PeriodicalId\":50685,\"journal\":{\"name\":\"Clinical & Translational Oncology\",\"volume\":\" \",\"pages\":\"\"},\"PeriodicalIF\":2.5000,\"publicationDate\":\"2025-08-21\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Clinical & Translational Oncology\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1007/s12094-025-04018-5\",\"RegionNum\":3,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"ONCOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical & Translational Oncology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s12094-025-04018-5","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0
摘要
背景：肢端黑色素瘤（AM）在非亚洲人种中并不常见。在非亚洲人群中存在的数据有限。目的：分析西班牙AM患者的免疫治疗活性。方法：我们分析了西班牙全国黑色素瘤组登记处AM的临床结果。结果：69例AM（17例III期，52例IV期）和724例皮肤黑色素瘤（CM）（190例III期，534例IV期），主要是非西班牙裔白人。关于IV期，AM患者年龄较大（中位73.6岁vs. 66.6岁，p = 0.001）， BRAF突变较少（9.6% vs. 60.7%, p = 0.0001）。一线免疫治疗（49 AM; 316 CM），有效率为15.0% vs 39.1% (p = 0.0033)，中位无进展生存期分别为5.5 (95% CI 3.97-8.23) vs 15.3个月（95% CI 8.97- 26.3） （p = 0.001），中位OS分别为17.3 (95% CI 13.32-39.97) vs 43.0个月（95% CI 30.81， NR） （p = 0.007）。III期AM更深（T4b为52.9% vs. 25.3%, p = 0.02）。在辅助抗pd -1治疗的患者（14 AM; 156 CM）中，AM的中位RFS为10.23个月（95% CI 6.0-NR），而CM的中位RFS为54.5-NR (p = 0.017)， 5年OS为36.1%对75.8% （p = 0.034）。结论：我们的数据证实了AM在西班牙人群中的不良预后。
Poor efficacy of anti PD-1 antibody based immunotherapy in patients with acral melanoma: results from the Spanish Melanoma Group (GEM) registry.
Background: Acral melanoma (AM) is uncommon in non-Asian race. Limited data exist in non-Asian population.
Objective: To analyze the activity of immunotherapy in patients diagnosed with AM in Spain.
Methods: We analyzed clinical outcomes of AM in the nationwide Spanish Melanoma Group Registry.
Results: 69 AM (17 stage III; 52 stage IV) and 724 cutaneous melanoma (CM) (190 stage III; 534 stage IV), predominantly non-Hispanic white. Regarding stage IV, AM patients were older (median 73.6 vs. 66.6 years, p = 0.001) and less often BRAF mutant (9.6% vs. 60.7%, p = 0.0001). First line immunotherapy (49 AM; 316 CM), response rate was 15.0% vs 39.1% (p = 0.0033), median progression free survival was 5.5 (95% CI 3.97-8.23) vs 15.3 months (95% CI 8.97- 26.3) (p = 0.001) and median OS was 17.3 (95% CI 13.32-39.97) versus 43.0 months (95% CI 30.81, NR) (p = 0.007), for AM and CM, respectively. Stage III AM were deeper (T4b in 52.9% vs. 25.3%, p = 0.02). In adjuvant anti PD-1-treated patients (14 AM; 156 CM) median RFS was 10.23 months (95% CI 6.0-NR) in AM versus NR (54.5-NR) in CM (p = 0.017) and 5 year OS was 36.1% vs. 75.8% (p = 0.034).
Conclusions: Our data confirms a poor outcome of AM in the Spanish population.
期刊介绍：
Clinical and Translational Oncology is an international journal devoted to fostering interaction between experimental and clinical oncology. It covers all aspects of research on cancer, from the more basic discoveries dealing with both cell and molecular biology of tumour cells, to the most advanced clinical assays of conventional and new drugs. In addition, the journal has a strong commitment to facilitating the transfer of knowledge from the basic laboratory to the clinical practice, with the publication of educational series devoted to closing the gap between molecular and clinical oncologists. Molecular biology of tumours, identification of new targets for cancer therapy, and new technologies for research and treatment of cancer are the major themes covered by the educational series. Full research articles on a broad spectrum of subjects, including the molecular and cellular bases of disease, aetiology, pathophysiology, pathology, epidemiology, clinical features, and the diagnosis, prognosis and treatment of cancer, will be considered for publication.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
